While responses to DNMT and HDAC inhibition were varied in prostate cancer cell lines, the changes to the epigenetic landscape that accompany gene and protein induction suggest modulation of epigenetic proteins in prostate cancer may be useful to re-express epigenetically silenced HLA-I in patients. The gene discussed is HDAC9; the disease is prostate carcinoma.